Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 6/20 | 0.62 |
| ▸ | TTK | P33981 | 4/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.58 |
| ▸ | PIM1 | P11309 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.50 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.50 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.50 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481767 | 0.82 | PRKCI (0.55) | MAP2K4TTKMAPK8PIM1MAPK1 | |
| SCHEMBL5374481 | 0.80 | MAP2K4 (0.67) | MAP2K4TTKMAPK8PIM1MAPK1 | |
| SCHEMBL5435640 | 0.80 | AURKA (0.56) | MAP2K4TTKMAPK1MAPKAPK3MAPK6 | |
| SCHEMBL5801740 | 0.79 | MAP2K4 (0.65) | MAP2K4TTKMAPK8PIM1MAPK1 | |
| SCHEMBL17801028 | 0.79 | CSNK1D (0.56) | MAP2K4TTKMAPK8MAPK1MAPKAPK3 | |
| SCHEMBL5383144 | 0.77 | MAP3K8 (0.42) | MAP2K4TTKMAPK8PIM1MAPK1 | |
| SCHEMBL22819366 | 0.77 | MAP2K4 (1.00) | MAP2K4TTKMAPK8PIM1MAPK1 | |
| SCHEMBL5377609 | 0.76 | MAP2K4 (0.65) | MAP2K4TTKMAPK8PIM1MAPK1 | |
| SCHEMBL5377947 | 0.75 | MAP2K4 (0.63) | MAP2K4TTKMAPK8PIM1MAPK1 | |
| SCHEMBL12073910 | 0.74 | TTK (0.65) | MAP2K4TTKMAPK8MAPK1MAPKAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | claimed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | MAP2K4 130/4885TTK 1198/4885MAPK8 26/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | MAP2K4 3021/4885TTK 2139/4885MAPK8 3017/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | MAP2K4 385/4885TTK 714/4885MAPK8 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.